DaVita (DVA) Set to Announce Quarterly Earnings on Thursday

DaVita (NYSE:DVA) will be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect DaVita to post earnings of $1.96 per share for the quarter. DaVita has set its FY24 guidance at $8.70-9.80 EPS and its FY 2024 guidance at 8.700-9.800 EPS.Investors interested in listening to the company’s conference call can do so using this link.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter last year, the firm earned $1.11 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts expect DaVita to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

DaVita Stock Performance

NYSE:DVA opened at $139.01 on Wednesday. The company’s 50-day moving average is $132.44 and its two-hundred day moving average is $111.30. The firm has a market capitalization of $12.19 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.19 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita has a 1-year low of $71.51 and a 1-year high of $141.54.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DVA shares. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Barclays started coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price objective on the stock. UBS Group lifted their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. StockNews.com upgraded shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. Finally, Truist Financial lifted their target price on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a report on Tuesday, February 20th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DaVita presently has an average rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Activity

In related news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, COO Michael David Staffieri sold 29,488 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the sale, the chief operating officer now directly owns 37,687 shares in the company, valued at $4,515,279.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.